SAN DIEGO, CA, September 18, 2017 – Recros Medica, Inc., a development stage medical aesthetic device company focused on reducing skin laxity and focal contouring, announced today that Thomas A. Albright has been named President and CEO, and will also serve on the Company’s Board of Directors. Mr. Albright brings nearly 35 years of healthcare experience to Recros Medica, with medical aesthetic leadership roles since 2000.
Mr. Albright was previously CEO of Andrew Technologies since 2011. Earlier he was President of the Topical Aesthetic division of Syneron and before that was VP North American marketing at Nobel Biocare.
Mr. Albright initiated his medical aesthetics experience at Allergan in 2000, where he led the worldwide launches of BOTOX Cosmetic. He ended his tenure at Allergan in 2008 as VP BOTOX Global Strategic Marketing, collaborating with R&D on new therapeutic and next generation biologics. Mr. Albright also led the commercial development of Latisse, and served as Alliance Manager for the multi-functional Japan and China collaboration with Glaxo Smithkline.
“We are excited to have Tom lead our company as we develop this proprietary and patented technology. He brings extensive experience in medical aesthetics, leadership of multi-functional teams in product development, and a proven track record building brand awareness and demand,” said David F. Hale, Chairman of the Board for Recros Medica.
Mr. Albright stated, “I am very pleased to be a part of the Recros Medica team. We are developing important new treatments based on the company’s proprietary Rotational Fractional Resection technology. We believe these treatments will be in great demand by consumers and physicians seeking novel minimally invasive procedures. Additionally, our team has significant functional expertise in the development of products for medical aesthetics.”
This technology was invented by Dr. Edward Knowlton, who also invented the Thermage technology, which has played an important role in aesthetics. “We believe that Tom has the experience and knowledge of aesthetics as we develop and plan to commercialize this technology with plastic surgeons and dermatologists,” said Dr. Knowlton.
About Rotational Fractional Resection
Rotational Fractional Resection (RFR) is a unique and proprietary technology to decrease skin laxity and improve focal contour by removing excess skin and fat. RFR handheld devices utilize tiny rotating cutting tubes to directly remove small plugs of skin in areas of skin laxity. This minimally invasive procedure will be performed in a physician’s office, delivering surgery-like results without visible scarring.
About Recros Medica, Inc.
Recros Medica was founded in 2014 by serial aesthetic entrepreneurs to develop a new technology platform, with multiple clinical applications. The primary opportunity for this platform is the development of clinical applications for use by Dermatologists, Plastic Surgeons and other aesthetic physicians that treat skin laxity and focal aesthetic contour deformities.